knowledge -WSS

knowledge

author：hotspot 2025-09-28 22:28:38 - browse：5

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The benefits and risks of Eli Lilly’s treatment for Alzheimer’s disease were confirmed in detailed scientific disclosures Monday, paving the way for its full approval but leaving physicians with lingering questions about the medicine’s impact on patients as a new era in Alzheimer’s therapy unfolds.

The drug, called donanemab, showed a 35% slowing of Alzheimer’s disease progression relative to placebo in a clinical trial that enrolled 1,700 patients with early-stage disease. Numerically, that’s a modest, 3.3-point improvement on a 144-point survey, called the Integrated Alzheimer’s Disease Rating Scale, or iADRS, that combines measures of cognition and function, such as driving, managing finances, or carrying on conversations.

There was a similar benefit when donanemab’s efficacy was assessed using a more common measure of cognition called the Clinical Dementia Rating-Sum of Boxes, or CDR-SB. On that scale, the Lilly drug showed a 36% slowing of cognitive decline relative to placebo, or 0.68 points on an 18-point scale.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

entertainment

WSS

Vaccine advisory panel ACIP left half staffed by HHS

In key trial, Verve's treatment lowers cholesterol levels in patients

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

CRISPR pioneers react to Casgevy, first gene

PhRMA lawsuit over Medicare drug price negotiation tossed

World's first CRISPR

focus

knowledge

focus

Activists slam private health insurers over coverage restrictions

Childhood cancer progress stalls for Black, Hispanic kids: Report

Bright Health sells Medicare Advantage business to Molina

BioAge raises $170M for combination therapy with Zepbound

Malaria cases in Florida and Texas: Here’s what you need to know

The Readout: Gilead, Bernie Sanders, and other pharma news

Heart attack and stroke risk calculators need revising

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

George Santos makes 1st court appearance after pleading not guilty to 13 counts

How digital tools helped lower hypertension in marginalized patients

entertainment

To avoid data mishandling cases, universities eye AI and other tools

Key House Republican on health care plans exit from Congress

PhRMA lawsuit over Medicare drug price negotiation tossed

To avoid data mishandling cases, universities eye AI and other tools

Medicare threatens to cut off funding for HCA's Mission hospital

What we’ve learned from the Aduhelm mess

focus

entertainment

focus

leisure time